Analyst Call of the Year: Collins Stewart on Encysive (ENCY)
More News related to ALTH
- Allos Therapeutics (ALTH) Collaborates with Idis to Manage FOLOTYN Outside U.S.
- Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN(TM) (pralatrexate injection)
- Allos Therapeutics (ALTH) Launches COMPLETE Registery for PTCL Patients
- Allos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematology Annual Meeting
- Allos Therapeutics (ALTH) Issued U.S. Patent for FOLOTYN T-Cell Lymphoma Treatment
More News related to ARRY
- Array BioPharma to Present at the Piper Jaffray Healthcare Conference
- UBS Upgrades Array BioPharma (ARRY) to Buy
- Array BioPharma (ARRY) Reports Q1 Loss of $0.52, Beats by 3c
- Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2010
- Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2010 on November 2, 2009
More News related to CYCC
- Cyclacel to Host Conference Call on Monday, December 7 to Discuss New Phase 2 Sapacitabine Data to be Presented at ASH
- Sapacitabine Phase 1 Data Published in Acute Leukemia and Myelodysplastic Syndromes
- NYSSA Presents 13th Annual Biotech and Specialty Pharmaceuticals Conference
- Cyclacel Pharmaceuticals to Present Sapacitabine Phase 2 AML & MDS Data at the Upcoming American Society of Hematology Meeting
- Cyclacel Pharmaceuticals Announces Third Quarter 2009 Financial Results
More News related to Insiders' Blog
- After Month's Of Gains, Gold Gives A Little Back Today (GDX, GLD, DGL, More)
- Office Supplies Cos. Up On Jobs Report: OMX, SPLS, ODP
- Synovus Financial (SNV) Running Up on FBR Upgrade
- Staffing Service Stocks Higher As Job Creation Now In Sight: MAN, MWW, RHI, KELYA, TBI, SFN, ASGN
- Novartis for Alcon (ACL)? Novartis Says "No" But Market Says "Yes"
Normally, Wall Street analysts get beat up in the media for their bad calls. So today we wanted to highlight an outstanding call by an analyst.
The stock: Encysive Pharmaceuticals Inc. (Nasdaq: ENCY).
The analyst: Andrew Fein at Collins Stewart
Yesterday, Fein upgraded Encysive to Buy. Today, the company announced a deal to be acquired by Pfizer (NYSE: PFE) for $2.35 per share, a huge premium to yesterday's $1.08 close. If you followed Fein's advice and bought the stock yesterday before the close you would be up over 100% today. Friday's close was $0.85, so if you bought yesterday morning, after the call, you would be up even more.
Fein was positive on Encysive's pulmonary hypertension drug THELIN in the EU and potential US approval. Pfizer saw the same thing and jumped at the chance to buy the entire company.
Great Call!
Some other pharmaceutical stocks Fein has Buy ratings on: Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH), United Therapeutics Corp. (Nasdaq: UTHR), Array BioPharma, Inc. (Nasdaq: ARRY), GTC Biotherapeutics, Inc. (Nasdaq: GTCB), OSI Pharmaceuticals Inc. (Nasdaq: OSIP), Tercica Inc. (Nasdaq: TRCA), Metabasis Therapeutics Inc. (Nasdaq: MBRX), Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), Rosetta Genomics, Ltd. (Nasdaq: ROSG), Insmed Incorporated (Nasdaq: INSM), Hana Biosciences Inc. (Nasdaq: HNAB), Allos Therapeutics, Inc. (Nasdaq: ALTH), Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS).
Related Categories
Insiders' BlogTrader Talk
Stocks Mentioned
+0.16
-0.02Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
INSM
Dan Gillespie on Feb 20, 2008 03:42 PMA $3.00 dollar stock trading below a $1.00.